{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:16:15Z","timestamp":1765170975686,"version":"3.46.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paclitaxel is a widely used chemotherapeutic agent with known vesicant properties. Extravasation is rare, but it can result in significant local tissue injury. There is no consensus on the optimal management strategy, and recommendations differ significantly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 63-year-old woman with metastatic cervical cancer who experienced a large-volume paclitaxel extravasation during a peripheral infusion. Management involved immediate subcutaneous administration of hyaluronidase around the affected area, followed by repeated applications of dry warm compresses. The patient reported only mild discomfort during treatment, and the local cutaneous symptoms resolved within days. Despite effective local management, the patient developed persistent paresthesia in the extravasated limb, later diagnosed as sensory neuropathy affecting the ulnar nerve. This was accompanied by lower limb neuropathy, likely related to the systemic paclitaxel exposure. Paclitaxel was discontinued, and the patient continued palliative treatment with carboplatin monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on our literature search, this appears to be the first documented case of high-volume paclitaxel extravasation successfully managed with both hyaluronidase and dry warmth. The intervention proved to be effective in preventing severe local tissue injury, although it did not mitigate neurotoxic effects. Further research is needed to establish standardized management protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1699608","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:12:48Z","timestamp":1765170768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Successful management of high-volume paclitaxel extravasation with hyaluronidase and dry warm compresses"],"prefix":"10.3389","volume":"15","author":[{"given":"Boris","family":"Dud\u00edk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maro\u0161","family":"Kunderl\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Mri\u0148\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Luk\u00e1\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanda","family":"U\u0161\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1n","family":"Klimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103932","article-title":"Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology","volume":"9","author":"Matsumoto","year":"2024","journal-title":"ESMO Open"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1758834013510546","article-title":"Taxanes: vesicants, irritants, or just irritating","volume":"6","author":"Barbee","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"B3","volume-title":"Summary of Product Characteristics: Paclitaxel Sandoz 6 mg\/mL concentrate for solution for infusion","year":""},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-003-0441-0","article-title":"A review of clinical experience with paclitaxel extravasations","volume":"11","author":"Stanford","year":"2003","journal-title":"Support Care Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15348","article-title":"Paclitaxel extravasation treated with systemic corticosteroids","volume":"47","author":"Cheour","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i26.7840","article-title":"Extravasation of chemotherapeutic drug from an implantable intravenous infusion port in a child: A case report","volume":"9","author":"Lv","year":"2021","journal-title":"World J Clin Cases"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1534112","article-title":"Case report: a successful multidisciplinary approach to doxorubicin extravasation from a PICC-port in a patient with breast cancer","volume":"15","author":"Calabr\u00f2","year":"2025","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_457_19","article-title":"Extent of extravasation: Patients on parenteral plant alkaloids","volume":"19","author":"Somayaji","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3892\/or.3.5.973","article-title":"Clinical course and management of paclitaxel extravasation","volume":"3","author":"Du Bois","year":"1996","journal-title":"Oncol Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds294","article-title":"ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO\u2013EONS clinical practice guidelines","volume":"23","author":"Fidalgo","year":"2012","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1188\/25.CJON.384-399","article-title":"ONS\/ASCO guideline on the management of antineoplastic extravasation","volume":"29","author":"Thomas","year":"2025","journal-title":"Clin J Oncol Nurs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.18.1320-a","article-title":"Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation","volume":"88","author":"Hidalgo","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_1982_22","article-title":"An up-to-date view of paclitaxel-induced peripheral neuropathy","volume":"19","author":"Wu","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.763229","article-title":"A systematic review and meta-analysis of the effectiveness of neuroprotectants for paclitaxel-induced peripheral neuropathy","volume":"11","author":"Leen","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2016.11.015","article-title":"Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects","volume":"288","author":"Gornstein","year":"2017","journal-title":"Exp Neurol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1699608\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:12:49Z","timestamp":1765170769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1699608\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":16,"alternative-id":["10.3389\/fonc.2025.1699608"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1699608","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1699608"}}